IRAK-4 inhibitors for inflammation

Current Topics in Medicinal Chemistry

Volumn 9, Issue 8, 2009, Pages 724-737

  Wang, Zhulun ^a   Wesche, Holger ^a   Stevens, Tracey ^b   Walker, Nigel ^a   Yeh, Wen Chen ^a  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

Author keywords

Binding mode; Interleukin 1 receptor associated kinase (IRAK); IRAK 4 inhibitors; Kinase inhibitors; X ray crystal structure

Indexed keywords

ACYL 2 AMINOBENZIMIDAZOLE INHIBITOR; ADENOSINE TRIPHOSPHATASE; ARGININE; ASPARTIC ACID; CYTOKINE RECEPTOR ANTAGONIST; IMIDAZOL[1,2 A]PYRIDINE INHIBITOR; IMIDAZOL[1,2 B]PYRIDAZINE INHIBITOR; INDAZOLE INHIBITOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 4 RECEPTOR INHIBITOR; LEUCINE; LYSINE; PROLINE; PYRIDINE AMIDE INHIBITOR; SERINE; STAUROSPORINE; THIAZOLE INHIBITOR; THREONINE; UNCLASSIFIED DRUG; VALINE;

AMINO TERMINAL SEQUENCE; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HYDROPHOBICITY; IMMUNITY; INFLAMMATION; NONHUMAN; PHARMACOPHORE; RESIDUE ANALYSIS; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; HUMANS; INFLAMMATION; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS;

EID: 70350129230     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789044407     Document Type: Review

References (67)

1. Li, S.; Strelow, A.; Fontana, E. J.; Wesche, H. IRAK-4: A novel member of the IRAK family with the properties of an IRAK-kinase. Proc. Natl. Acad. Sci. USA 2002, 99, 5567-5572.
2. O'Neill, L. A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immun. Rev. 2008, 226, 10-18.
3. Takeda, K.; Akira, S. TLR signaling pathways. Semin. Immunol. 2004, 16, 3-9.
4. Akira, S. TLR signaling. Curr. Top. Microbiol. Immunol. 2006, 311, 1-16.
5. Gearing, A. J. Targeting toll-like receptors for drug development: A summary of commercial approaches. Immunol. Cell Biol. 2007, 85, 490-494.
6. Suzuki, N.; Suzuki, S.; Duncan, G. S.; Millar, D. G.; Wada, T.; Mirtsos, C.; Takada, H.; Wakeham, A.; Itie, A.; Li, S.; Penninger, J. M.; Wesche, H.; Ohashi, P. S.; Mak, T. W.; Yeh, W-C. Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 2002, 416, 750-756.
7. Picard, C.; Puel, A.; Bonnet, M.; Ku, C. L.; Bustamante, J.; Yang, K.; Soudais, C.; Dupuis, S.; Feinberg, J.; Fieschi, C.; Elbim, C.; Hitchcock, R.; Lammas, D.; Davies, G.; Al-Ghonaium, A.; Al-Rayes, H.; Al-Jumaah, S.; Al-Hajjar, S.; Al-Mohsen, I. Z.; Frayha, H. H.; Rucker, R.; Hawn, T. R.; Aderem, A.; Tufenkeji, H.; Haraguchi, S.; Day, N. K.; Good, R. A.; Gougerot-Pocidalo, M-A.; Ozinsky, A.; Casanova, J-L. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299, 2076-2079.
8. Medvedev, A. E.; Thomas, K.; Awomoyi, A.; Kuhns, D. B.; Gallin, J. I.; Li, X.; Vogel, S. N. Cutting edge: Expression of IL-1 receptor-associated kinase-4 (IRAK-4) proteins with mutations identified in a patient with recurrent bacterial infections alters normal IRAK-4 interaction with components of the IL-1 receptor complex. J. Immunol. 2005, 174, 6587-6591.
9. Ku, C-L.; von Bernuth, H.; Picard, C.; Zhang, S-Y.; Chang, H-H.; Yang, K.; Chrabieh, M.; Issekutz, A. C.; Cunningham, C. K.; Gallin, J.; Holland, S. M.; Roifman, C.; Ehl, S.; Smart, J.; Tang, M.; Barrat, F. J.; Levy, O.; McDonald, D.; Day-Good, N. K.; Miller, R.; Takada, H.; Hara, T.; Al-Hajjar, S.; Al-Ghonaium, A.; Speert, D.; Sanlaville, D.; Li, X.; Geissmann, F.; Vivier, E.; Maródi, L.; Garty, B-Z.; Chapel, H.; Rodriguez-Gallego, C.; Bossuyt, X.; Abel, L.; Puel, A.; Cassanova, J-L. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 2007, 204, 2407-2422.
10. Ku, C-L.; Yang, K.; Bustamante, J.; Puel, A.; von Bernuth, H.; Santos, O. F.; Lawrence, T.; Chang, H-H.; Al-Mousa, H.; Picard, C.; Cassanova, J-L. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol. Rev. 2005, 203, 10-20.
11. Cao, Z.; Henzel, W. J.; Gao, X. IRAK: A kinase associated with the interleukin-1 receptor. Science 1996, 271, 1128-1131.
12. Muzio, M.; Ni, J.; Feng, P.; Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997, 278, 1612-1615.
13. Wesche, H.; Gao, X.; Li, X.; Kirschning, C. J.; Stark, G. R.; Cao, Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J. Biol. Chem. 1999, 274, 19403-19410.
14. Janssens, S.; Beyaert, R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell 2003, 11, 293-302.
15. Huang, Y. S.; Misior, A.; Li, L. W. Novel role and regulation of the interleukin-1 receptor associated kinase (IRAK) family proteins. Cell Mol. Immun. 2005, 2, 36-39.
16. Ringwood, L.; Li, L. The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation. Cytokine 2008, 42, 1-7
17. Kawagoe, T.; Sato, S.; Matsushita, K.; Kato, H.; Matsui, K.; Kumagai, Y.; Saitoh, T.; Kawai, T.; Takeuchi, O.; Akira, S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2.[see comment]. Nat. Immunol. 2008, 9, 684-691.
18. Kobayashi, K.; Hernandez, L. D.; Galan, J. E.; Janeway, C. A., Jr.; Medzhitov, R.; Flavell, R. A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110, 191-202.
19. Kanakaraj, P.; Schafer, P. H.; Cavender, D. E.; Wu, Y.; Ngo, K.; Grealish, P. F.; Wadsworth, S. A.; Peterson, P. A.; Siekierka, J. J.; Harris, C. A.; Fung-Leung, W-P. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J. Exp. Med. 1998, 187, 2073-2079.
20. Thomas, J. A.; Allen, J. L.; Tsen, M.; Dubnicoff, T.; Danao, J.; Liao, X. C.; Cao, Z.; Wasserman, S. A. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J. Immunol. 1999, 163, 978-984.
21. Uematsu, S.; Sato, S.; Yamamoto, M.; Hirotani, T.; Kato, H.; Takeshita, F.; Matsuda, M.; Coban, C.; Ishii, K. J.; Kawai, T.; Takeuchi, O.; Akira, S. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med. 2005, 201, 915-923.
22. Shelton, C. A.; Wasserman, S. A. pelle encodes a protein kinase required to establish dorsoventral polarity in the Drosophila embryo. Cell 1993, 72, 515-525.
23. Kawagoe, T.; Sato, S.; Jung, A.; Yamamoto, M.; Matsui, K.; Kato, H.; Uematsu, S.; Takeuchi, O.; Akira, S. Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J. Exp. Med. 2007, 204, 1013-1024.
24. Kawai, T.; Akira, S. Toll-like receptor and RIG-I-like receptor signaling. Ann. NY Acad. Sci. 2008, 1143, 1-20
25. Honda, K.; Yanai, H.; Mizutani, T.; Negishi, H.; Shimada, N.; Suzuki, N.; Ohba, Y.; Takaoka, A.; Yeh, W. C.; Taniguchi, T. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 2004, 101, 15416-15421.
26. Isnardi, I.; Ng, Y-S.; Srdanovic, I.; Motaghedi, R.; Rudchenko, S.; von Bernuth, H.; Zhang, S-Y.; Puel, A.; Jouanguy, E.; Picard, C.; Garty, B-Z.; Camcioglu, Y.; Doffinger, R.; Kumararatne, D.; Davies, G.; Gallin, J. I.; Haraguchi, S.; Day, N. K.; Casanova, J-L. Meffre, E. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans.[see comment]. Immunity 2008, 29, 746-757.
27. Zhang, S. Y.; Jouanguy, E.; Sancho-Shimizu, V.; von Bernuth, H.; Yang, K.; Abel, L.; Picard, C.; Puel, A.; Casanova, J. L. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immun. Rev. 2007, 220, 225-236.
28. Yang, K.; Puel, A.; Zhang, S.; Eidenschenk, C.; Ku, C-L.; Casrouge, A.; Picard, C.; von Bernuth, H.; Senechal, B.; Plancoulaine, S.; Al-Hajjar, S.; Al-Ghonauim, A.; Maródi, L.; Davidson, D.; Speert, D.; Roifman, C.; Garty, B-Z.; Ozinsky, A.; Barrat, F. J.; Coffman, R. L.; Miller, R. L.; Li, X.; Lebon, P.; Rodriguez-Gallego, H. C.; Geissmann, F.; Jouanguy, E.; Cassanova, J-L. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005, 23, 465-478.
29. Barrat, F. J.; Meeker, T.; Chan, J. H.; Guiducci, C.; Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37, 3582-3586.
30. Lye, E.; Mirtsos, C.; Suzuki, N.; Suzuki, S.; Yeh, W. C. The role of interleukin 1 receptor-associated kinase-4 (IRAK-4) kinase activity in IRAK-4-mediated signaling. J. Biol. Chem. 2004, 279, 40653-40658.
31. Koziczak-Holbro, M.; Joyce, C.; Gluck, A.; Kinzel, B.; Muller, M.; Tschopp, C.; Mathison, J. C.; Davis, C. N.; Gram, H. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression. J. Biol. Chem. 2007, 282, 13552-13560.
32. Koziczak-Holbro, M.; Joyce, C.; Gluck, A.; Kinzel, B.; Muller, M.; Gram, H. Solving the IRAK-4 enigma: Application of kinase-dead knock-in mice. Ernst Schering Found. Symp. Proc. 2007, 63-82.
33. Kim, T. W.; Staschke, K.; Bulek, K.; Yao, J.; Peters, K.; Oh, K-H.; Vandenburg, Y.; Xiao, H.; Qian, W.; Hamilton, T.; Min, B.; Sen, G.; Gilmour, R.; Li, X. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J. Exp. Med. 2007, 204, 1025-1036.
34. Lye, E.; Dhanji, S.; Calzascia, T.; Elford, A. R.; Ohashi, P. S. IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune responses. Eur. J. Immunol. 2008, 38, 870-876.
35. Arend, W. P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002, 13, 323-340.
36. Sivakumar, P. V.; Westrich, G. M.; Kanaly, S.; Garka, K.; Born, T. L.; Derry, J. M.; Viney, J. L. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50, 812-820.
37. Boraschi, D.; Dinarello, C. A. IL-18 in autoimmunity: Review. Eur. Cytokine Network 2006, 17, 224-252.
38. Huang, Q.; Ma, Y.; Adebayo, A.; Pope, R. M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthrit. Rheum. 2007, 56, 2192-2201.
39. Wang, Z.; Liu, J.; Sudom, A.; Ayres, M.; Li, S.; Wesche, H.; Powers, J. P.; Walker, N. P. Crystal structures of IRAK-4 kinase in complex with inhibitors: A serine/threonine kinase with tyrosine as a gatekeeper. Structure 2006, 14, 1835-1844.
40. Kuglstatter, A.; Villasenor, A. G.; Shaw, D.; Lee, S. W.; Tsing, S.; Niu, L.; Song, K. W.; Barnett, J. W.; Browner, M. F. Cutting edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. J. Immunol. 2007, 178, 2641-2645.
41. Lei, M.; Robinson, M. A.; Harrison, S. C. The active conformation of the PAK1 kinase domain. Structure 2005, 13, 769-778
42. Wan, W. Y.; Milner-White, E. J. A recurring two-hydrogen-bond motif incorporating a serine or threonine residue is found both at alpha-helical N termini and in other situations. J. Mol. Biol. 1999, 286, 1651-1662.
43. Wan, W. Y.; Milner-White, E. J. A natural grouping of motifs with an aspartate or asparagine residue forming two hydrogen bonds to residues ahead in sequence: Their occurrence at alpha-helical N termini and in other situations. J. Mol. Biol. 1999, 286, 1633-1649.
44. Schellman, C. The alphaL conformation at the ends of helices. In Protein Folding, Jaenicke, R. Ed.; Elsevier: Amsterdam, 1980; p. 53.
45. Cheng, H.; Addona, T.; Keshishian, H.; Dahlstrand, E.; Lu, C.; Dorsch, M.; Li, Z.; Wang, A.; Ocain, T. D.; Li, P.; Parsons, T. F.; Jaffee, B.; Xu, Y. Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop. Biochem. Biophys. Res. Commun. 2007, 352, 609-616.
46. Zheng, J.; Knighton, D. R.; ten Eyck, L. F.; Karlsson, R.; Xuong, N.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993, 32, 2154-2161.
47. Russo, A. A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696-700.
48. Canagarajah, B. J.; Khokhlatchev, A.; Cobb, M. H.; Goldsmith, E. J. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 1997, 90, 859-869.
49. Yamaguchi, H.; Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996, 384, 484-489.
50. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 1997, 16, 5572-5581.
51. Brown, N. R.; Noble, M. E.; Endicott, J. A.; Johnson, L. N. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell Biol. 1999, 1, 438-443.
52. Johnson, L. N.; Noble, M. E.; Owen, D. J. Active and inactive protein kinases: Structural basis for regulation. Cell 1996, 85, 149-158.
53. Favelyukis, S.; Till, J. H.; Hubbard, S. R.; Miller, W. T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat. Struct. Biol. 2001, 8, 1058-1063.
54. Boggon, T. J.; Li, Y.; Manley, P. W.; Eck, M. J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005, 106, 996-1002.
55. Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 1999, 7, 651-661.
56. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805.
57. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109, 275-282.
58. Durand-Reville, T.; Jewell, C.; Hammond, C.; Chin, D. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder. PCT Int. Appl. WO2008030579A3, 2008.
59. Powers, J. P.; Li, S.; Jaen, J. C.; Liu, J.; Walker, N. P. C.; Wang, Z.; Wesche, H. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg. Med. Chem. Lett. 2006, 16, 2842-2845.
60. Buckley, G. M., Gowers, L., Higueruelo, A. P., Jenkins, K., Mack, S. R., Morgan, T., Parry, D. M., Pitt, W. R., Rausch, O., Richard, M. D., Sabin, V.; Fraser, J. L. IRAK-4 inhibitors. Part 1: A series of amides. Bioorg. Med. Chem. Lett. 2008, 18, 3211-3214.
61. Buckley, G. M.; Fosbeary, R.; Fraser, J. L.; Gowers, L.; Higueruelo, A. P.; James, L. A.; Jenkins, K.; Mack, S. R.; Morgan, T.; Parry, D. M.; Pitt, W. R.; Rausch, O.; Richard, M. D.; Sabin, V. IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines. Bioorg. Med. Chem. Lett. 2008, 18, 3656-3660.
62. Buckley, G. M.; Ceska, T. A.; Fraser, J. L.; Gowers, L.; Groom, C. R.; Higueruelo, A. P.; Jenkins, K.; Mack, S. R.; Morgan, T.; Parry, D. M.; Pitt, W. R.; Rausch, O.; Richard, M. D.; Sabin, V. IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding. Bioorg. Med. Chem. Lett. 2008, 18, 3291-3295.
63. Song, K. W.; Talamas, F. X.; Suttmann, R. T.; Olson, P. S.; Barnett, J. W.; Lee, S. W.; Thompson, K. D.; Jin, S.; Hekmat-Nejad, M.; Cai, T. Z.; Manning, A. M.; Hill, R. J.; Wong, B. R. The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cells. Mol. Immunol. 2009, 46, 1458-1466.
64. Guckian, K.; Jewell, C.; Conlan, P.; Lin, E. Y.-S.; Chan, T. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase. PCT Int. Appl. WO2008030584A3, 2008.
65. Sayle, K. L.; Bentley, J.; Boyle, F. T.; Calvert, A. H.; Cheng, Y.; Curtin, N. J.; Endicott, J. A.; Golding, B. T.; Hardcastle, I. R.; Jewsbury, P.; Mesguiche, V.; Newell, D. R.; Noble, M. E. M.; Parsons, R. J.; Pratt, D. J.; Wang, L. Z.; Griffin, R. J. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 2003, 13, 3079-3082.
66. Bingham, A. H.; Davenport, R. J.; Gowers, L.; Knight, R. L.; Lowe, C.; Owen, D. A.; Parry, D. M.; Pitt, W. R. A novel series of potent and selective IKK2 inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 409-412.
67. Yamin, T. T.; Miller, D. K. The interleukin-1 receptor-associated kinase is degraded by proteasomes following its phosphorylation. J. Biol. Chem. 1997, 272, 21540-21547.